cut
volum
6
number
11
april
25
1993
health
infocom
network
medic
newslett
editor
david
dodel
dmd
10250
north
92nd
street
suit
210
scottsdal
arizona
852584599
usa
telephon
1
602
8601121
fax
1
602
4511165
compil
copyright
1993
david
dodel
dmd
right
reserv
licens
herebi
grant
republish
electron
media
fee
charg
long
text
copyright
notic
licens
attach
intact
republish
portion
portion
health
infocom
network
newslett
distribut
biweekli
articl
medic
natur
welcom
articl
pleas
contact
editor
inform
submit
interest
join
autom
distribut
system
pleas
contact
editor
internet
davidstatcom
fidonet
111415
bitnet
atw1hasuacad
listserv
mednewsasuacadbitnet
internet
mednewsasuvminreasuedu
anonym
ftp
vm1nodakedu
notif
list
hicnnotifyrequeststatcom
fax
deliveri
contact
editor
inform
b
l
e
f
c
n
e
n
1
center
diseas
control
prevent
mmwr
23
april
1993
rate
cesarean
deliveri
1
malaria
among
us
embassi
personnel
5
fda
approv
hib
vaccin
childreninf
8
2
dental
news
workshop
explor
oral
manifest
hiv
infect
11
3
food
drug
administr
news
fda
approv
depo
provera
inject
contracept
14
new
rule
speed
approv
drug
lifethreaten
ill
16
4
articl
research
promis
preventingslow
blind
retin
diseas
18
affluent
diet
increas
risk
heart
diseas
20
5
gener
announc
public
health
profession
nation
cancer
institut
23
public
patient
avail
nation
cancer
institut
30
6
aid
news
summari
aid
daili
summari
april
19
april
23
1993
38
7
aid
statist
worldwid
aid
statist
48
hicnet
medic
newslett
page
volum
6
number
11
april
25
1993
center
diseas
control
prevent
mmwr
rate
cesarean
deliveri
unit
state
1991
sourc
mmwr
4215
date
apr
23
1993
cesarean
deliveri
account
nearli
1
million
approxim
4
million
annual
deliveri
unit
state
sinc
1986
tabl
1
cesarean
rate
unit
state
third
highest
among
21
report
countri
exceed
brazil
puerto
rico
1
report
present
data
cesarean
deliveri
cdc
nation
hospit
discharg
survey
nhd
1991
compar
data
previou
year
data
discharg
shortstay
nonfeder
hospit
collect
annual
sinc
1965
nhd
conduct
cdc
nation
center
health
statist
1991
medic
demograph
inform
abstract
sampl
274000
inpati
discharg
484
particip
hospit
1991
cesarean
vagin
birth
prior
cesarean
vbac
present
report
base
weight
nation
estim
nhd
sampl
approxim
31000
11
women
discharg
deliveri
estim
number
live
birth
type
deliveri
calcul
appli
cesarean
rate
nhd
live
birth
nation
vital
registr
data
therefor
estim
number
cesarean
report
agre
previous
publish
data
base
sole
nhd
2
state
differ
analysi
signific
95
confid
level
base
twotail
ttest
critic
valu
196
1991
235
cesarean
per
100
deliveri
rate
1990
similar
rate
19861989
tabl
1
primari
cesarean
rate
ie
number
first
cesarean
per
100
deliveri
women
previou
cesarean
19861991
also
stabl
rang
168
175
1991
cesarean
rate
south
276
significantli
p005
higher
rate
west
198
midwest
218
northeast
226
rate
higher
mother
age
greater
equal
30
year
younger
women
proprietari
hospit
nonprofit
govern
hospit
hospit
fewer
300
bed
larger
hospit
deliveri
blue
crossblu
shield
privat
insur
expect
sourc
payment
sourc
payment
tabl
2
pattern
character
primari
cesarean
deliveri
sinc
earli
1970
number
percentag
birth
older
women
increas
howev
age
distribut
mother
1991
remain
1986
overal
cesarean
rate
1991
would
233
essenti
235
observ
base
nhd
approxim
4111000
live
birth
1991
hicnet
medic
newslett
page
1
volum
6
number
11
april
25
1993
estim
966000
235
cesarean
deliveri
estim
338000
350
birth
repeat
cesarean
628000
650
primari
cesarean
sinc
1986
approxim
600000
primari
cesarean
perform
annual
1986
85
women
previou
cesarean
deliv
vagin
compar
242
1991
cesarean
1991
350
associ
previou
cesarean
304
dystocia
ie
failur
labor
progress
117
breech
present
92
fetal
distress
137
specifi
complic
averag
hospit
stay
deliveri
1991
28
day
comparison
hospit
stay
primari
cesarean
deliveri
45
day
repeat
cesarean
42
day
nearli
twice
durat
vbac
deliveri
22
day
vagin
deliveri
vbac
23
day
1986
averag
hospit
stay
deliveri
32
day
primari
cesarean
52
day
repeat
cesarean
47
day
vbac
nonvbac
vagin
deliveri
27
26
day
respect
report
offic
vital
health
statist
system
nation
center
health
statist
cdc
editori
note
cesarean
rate
unit
state
steadili
increas
1965
1986
howev
find
report
indic
rate
stabl
sinc
1986
3
littl
evid
matern
child
health
statu
improv
time
cesarean
associ
increas
risk
complic
childbirth
nation
health
object
year
2000
4
reduc
overal
cesarean
rate
15
fewer
per
100
deliveri
primari
cesarean
rate
12
fewer
per
100
deliveri
object
148
postpartum
complic
includ
urinari
tract
wound
infect
may
account
part
longer
hospit
stay
cesarean
deliveri
vagin
birth
5
moreov
prolong
hospit
stay
cesarean
deliveri
substanti
increas
healthcar
cost
exampl
1991
averag
cost
cesarean
vagin
deliveri
7826
4720
respect
addit
cost
cesarean
deliveri
includ
611
physician
fee
2495
hospit
charg
6
cesarean
rate
1991
15
year
2000
object
instead
235
number
cesarean
birth
would
decreas
349000
617000
versu
966000
result
save
1
billion
physician
fee
hospit
charg
despit
steadi
increas
vbac
rate
sinc
1986
sever
factor
may
imped
progress
toward
year
2000
nation
health
object
cesarean
deliveri
exampl
vbac
rate
substanti
reflect
number
women
offer
trial
labor
increasingli
encourag
sinc
1982
7
women
offer
trial
labor
5070
could
deliv
vagin
7
level
alreadi
achiev
mani
hospit
8
trial
labor
routin
offer
46
hospit
survey
1984
recent
year
hicnet
medic
newslett
page
2
volum
6
number
11
april
25
1993
nation
data
avail
9
vbac
rate
accord
nhd
data
57
year
2000
object
specifi
vbac
rate
35
base
women
prior
cesarean
regardless
whether
trial
labor
attempt
reach
overal
cesarean
rate
goal
howev
increas
vbac
rate
need
combin
substanti
reduct
primari
rate
one
hospit
succeed
reduc
rate
cesarean
deliveri
appli
object
criteria
four
common
indic
cesarean
deliveri
requir
second
opinion
institut
peerreview
process
10
recommend
decreas
cesarean
deliveri
rate
includ
elimin
incent
physician
hospit
equal
reimburs
vagin
cesarean
deliveri
public
dissemin
physician
hospitalspecif
cesarean
deliveri
rate
increas
public
awar
differ
practic
address
malpractic
concern
may
import
factor
maintain
high
rate
cesarean
deliveri
4
refer
1
notzon
fc
intern
differ
use
obstetr
intervent
jama
1990
263328691
2
grave
ej
nch
1991
summari
nation
hospit
discharg
survey
hyattsvil
maryland
us
depart
health
human
servic
public
health
servic
cdc
1993
advanc
data
227
3
taffel
sm
placek
pj
kosari
cl
us
cesarean
section
rate
1990
updat
birth
199219212
4
public
health
servic
healthi
peopl
2000
nation
health
promot
us
depart
health
human
servic
public
health
servic
1991
dhh
public
phs9150212
5
danforth
dn
cesarean
section
jama
19852538118
6
hospit
insur
associ
america
tabl
415
cost
matern
care
physician
fee
hospit
charg
censu
region
base
consum
price
index
1991
1992
sourc
book
health
insur
data
washington
dc
hospit
insur
associ
america
1992
7
committe
obstetr
acog
committe
opinion
64
guidelin
vagin
deliveri
previou
cesarean
birth
washington
dc
american
colleg
obstetrician
gynecologist
1988
hicnet
medic
newslett
page
3
volum
6
number
11
april
25
1993
8
rosen
mg
dickinson
jc
vagin
birth
cesarean
metaanalysi
indic
success
obstet
gynecol
1990768659
9
shiono
ph
fielden
jg
mcnelli
rhoad
gg
pears
wh
recent
trend
cesarean
birth
trial
labor
rate
unit
state
jama
19872574947
10
myer
sa
gleicher
n
success
program
lower
cesareansect
rate
n
engl
j
med
198831915116
use
trade
name
commerci
sourc
identif
impli
endors
public
health
servic
us
depart
health
human
servic
hicnet
medic
newslett
page
4
volum
6
number
11
april
25
1993
malaria
among
us
embassi
personnel
kampala
uganda
1992
sourc
mmwr
4215
date
apr
23
1993
treatment
prevent
malaria
africa
becom
challeng
complex
problem
increas
drug
resist
although
risk
acquir
malaria
us
citizen
depend
station
oversea
gener
low
risk
vari
substanti
unpredict
may
1992
offic
medic
servic
depart
state
omsdo
cdc
notifi
increas
number
malaria
case
among
offici
us
personnel
station
kampala
uganda
review
health
record
embassi
health
unit
ehu
kampala
indic
27
case
malaria
diagnos
offici
personnel
march
june
1992
compar
two
case
period
1991
ehu
omsdo
cdc
conduct
investig
confirm
report
malaria
case
identifi
potenti
risk
factor
malaria
among
us
embassi
personnel
report
summar
result
investig
malaria
blood
smear
25
27
report
casepati
avail
review
omsdo
cdc
case
malaria
confirm
slide
posit
plasmodium
sp
25
person
17
slide
confirm
malaria
questionnair
distribut
person
serv
ehu
obtain
inform
resid
activ
use
malaria
chemoprophylaxi
use
person
protect
measur
ie
use
bednet
insect
repel
window
door
screen
wear
long
sleev
pant
even
157
person
elig
survey
128
82
respond
risk
malaria
associ
sex
locat
resid
kampala
although
risk
malaria
higher
among
children
age
less
equal
15
year
632
19
among
person
greater
15
year
1194
12
differ
signific
rel
risk
rr16
95
confid
interv
ci0640
eightytwo
percent
case
occur
among
person
live
kampala
15
year
compar
live
less
1
year
travel
outsid
kampala
area
rural
set
associ
increas
risk
malaria
four
malaria
chemoprophylaxi
regimen
use
person
particip
survey
mefloquin
chloroquin
proguanil
chloroquin
alon
proguanil
alon
addit
23
18
person
respond
use
malaria
chemoprophylaxi
risk
malaria
significantli
lower
among
person
use
either
mefloquin
chloroquin
proguanil
888
9
among
person
use
regimen
prophylaxi
937
24
rr04
95
ci0209
twelv
person
use
prophylaxi
report
side
effect
fear
possibl
side
effect
reason
risk
malaria
lower
among
person
report
use
bednet
hicnet
medic
newslett
page
5
volum
6
number
11
april
25
1993
time
227
7
among
person
sometim
rare
use
bednet
1599
15
rr05
95
ci0120
risk
malaria
also
lower
among
person
consist
use
insect
repel
even
016
compar
rare
use
repel
17110
15
rr0
upper
95
confid
limit12
risk
malaria
associ
failur
window
door
screen
wear
long
sleev
pant
even
result
investig
ehu
staff
review
personnel
need
use
compli
recommend
malaria
chemoprophylaxi
regimen
ehu
staff
also
emphas
need
use
person
protect
measur
made
plan
obtain
insecticideimpregn
bednet
provid
window
door
screen
personnel
report
us
embassi
health
unit
kampala
uganda
offic
medic
svc
dept
state
washington
dc
malaria
br
div
parasit
diseas
nation
center
infecti
diseas
cdc
editori
note
uganda
increas
malaria
among
us
personnel
attribut
poor
adher
recommend
malaria
chemoprophylaxi
regimen
use
person
protect
measur
period
increas
malaria
transmiss
intensifi
chloroquin
resist
subsaharan
africa
find
report
underscor
need
provid
initi
continu
counsel
regard
malaria
prevent
person
live
abroad
malariaendem
area
prevent
measur
also
import
shortterm
travel
area
mefloquin
effect
prophylaxi
regimen
africa
area
chloroquineresist
p
falciparum
howev
area
eg
thailand
resist
mefloquin
may
limit
effect
africa
efficaci
mefloquin
compar
chloroquin
alon
prevent
infect
p
falciparum
92
1
mefloquin
safe
well
toler
given
250
mg
per
week
2year
period
risk
seriou
advers
reaction
possibl
associ
mefloquin
prophylaxi
eg
psychosi
convuls
low
ie
1319
episod
per
100000
user
2
risk
less
sever
advers
reaction
eg
dizzi
gastrointestin
complaint
sleep
disturb
similar
antimalari
chemoprophylact
1
doxycyclin
similar
prophylact
efficaci
mefloquin
need
daili
dose
may
reduc
complianc
effect
regimen
34
chloroquin
alon
effect
prophylaxi
area
intens
chloroquin
resist
eg
southeast
asia
africa
africa
person
cannot
take
mefloquin
doxycyclin
chloroquin
proguanil
altern
although
less
effect
regimen
chloroquin
use
malaria
prevent
area
chloroquineresist
p
falciparum
report
countryspecif
recommend
prevent
malaria
inform
hicnet
medic
newslett
page
6
volum
6
number
11
april
25
1993
dosag
precaut
malaria
chemoprophylaxi
regimen
avail
health
inform
intern
travel
1992
ie
yellow
book
5
24
hour
day
telephon
fax
404
3324555
refer
1
lobel
ho
miani
eng
et
al
longterm
malaria
prophylaxi
weekli
mefloquin
peac
corp
volunt
effect
well
toler
regimen
lancet
199334184851
2
world
health
organ
review
central
nervou
system
advers
event
relat
antimalari
drug
mefloquin
19851990
geneva
world
health
organ
1991
public
whomal911063
3
pang
l
limsomwong
n
singharaj
p
prophylact
treatment
vivax
falciparum
malaria
lowdos
doxycyclin
j
infect
di
198815811247
4
pang
l
limsomwong
n
boudreau
ef
singharaj
p
doxycyclin
prophylaxi
falciparum
malaria
lancet
1987111614
5
cdc
health
inform
intern
travel
1992
atlanta
us
depart
health
human
servic
public
health
servic
199298
dhh
public
cdc928280
hicnet
medic
newslett
page
7
volum
6
number
11
april
25
1993
fda
approv
use
new
haemophilu
b
conjug
vaccin
combin
diphtheriatetanuspertussi
haemophilu
b
conjug
vaccin
infant
children
sourc
mmwr
4215
date
apr
23
1993
haemophilu
influenza
type
b
hib
conjug
vaccin
recommend
use
infant
sinc
1990
routin
use
infant
vaccin
contribut
substanti
declin
incid
hib
diseas
unit
state
13
vaccin
diphtheria
tetanu
pertussi
infanc
childhood
administ
routin
unit
state
sinc
late
1940
associ
greater
90
reduct
morbid
mortal
associ
infect
organ
increas
number
vaccin
routin
recommend
infant
high
prioriti
develop
combin
vaccin
allow
simultan
administr
fewer
separ
inject
food
drug
administr
fda
recent
licens
two
new
product
vaccin
children
diseas
1
haemophilu
b
conjug
vaccin
tetanu
toxoid
conjug
acthib
trademark
vaccin
hib
diseas
2
combin
diphtheria
tetanu
toxoid
wholecel
pertussi
vaccin
dtp
hib
conjug
vaccin
tetramun
trademark
combin
vaccin
formul
use
vaccin
children
diphtheria
tetanu
pertussi
hib
diseas
acthib
trademark
march
30
1993
fda
approv
new
haemophilu
b
conjug
vaccin
polyribosylribitol
phosphatetetanu
toxoid
conjug
prpt
manufactur
pasteur
merieux
serum
et
vaccin
distribut
acthib
trademark
connaught
laboratori
inc
swiftwat
pennsylvania
vaccin
licens
use
infant
threedos
primari
vaccin
seri
administ
age
2
4
6
month
previous
unvaccin
infant
711
month
age
receiv
two
dose
2
month
apart
previous
unvaccin
children
1214
month
age
receiv
one
dose
booster
dose
administ
15
month
age
recommend
children
previous
unvaccin
children
1559
month
age
receiv
singl
dose
requir
booster
90
infant
receiv
primari
vaccin
seri
acthib
trademark
consecut
dose
2
4
6
month
age
develop
geometr
mean
titer
antihaemophilu
b
polysaccharid
antibodi
greater
1
ugml
4
respons
similar
infant
receiv
recommend
seri
previous
licens
haemophilu
b
conjug
vaccin
efficaci
demonstr
prospect
trial
two
us
efficaci
trial
prpt
termin
earli
concomit
licensur
haemophilu
b
conjug
vaccin
hicnet
medic
newslett
page
8
volum
6
number
11
april
25
1993
use
infant
4
studi
case
invas
hib
diseas
detect
approxim
6000
infant
vaccin
prpt
studi
suggest
efficaci
prpt
vaccin
similar
licens
hib
vaccin
tetramun
trademark
march
30
1993
fda
approv
combin
diphtheria
tetanu
toxoid
wholecel
pertussi
vaccin
dtp
haemophilu
b
conjug
vaccin
tetramun
trademark
avail
lederlepraxi
biolog
pearl
river
new
york
combin
two
previous
licens
product
dtp
triimmunol
regist
manufactur
lederl
laboratori
pearl
river
new
york
haemophilu
b
conjug
vaccin
hibtit
regist
manufactur
praxi
biolog
inc
rochest
new
york
vaccin
licens
use
children
age
2
months5
year
protect
diphtheria
tetanu
pertussi
hib
diseas
indic
vaccin
dtp
vaccin
haemophilu
b
conjug
vaccin
coincid
base
demonstr
co
mparabl
higher
antibodi
respons
compon
two
vaccin
tetramun
trademark
expect
provid
protect
hib
well
diphtheria
tetanu
pertussi
equival
alreadi
licens
formul
dtp
haemophilu
b
vaccin
advisori
committe
immun
practic
acip
recommend
infant
receiv
primari
seri
one
licens
haemophilu
b
conjug
vaccin
begin
2
month
age
booster
dose
age
12
15
month
5
acip
also
recommend
infant
receiv
fourdos
primari
seri
diphtheria
tetanu
toxoid
pertussi
vaccin
2
4
6
1518
month
age
booster
dose
46
year
68
complet
statement
regard
recommend
use
acthib
trademark
tetramun
trademark
develop
report
offic
vaccin
research
review
center
biolog
evalu
research
food
drug
administr
div
immun
nation
center
prevent
svc
mening
special
pathogen
br
div
bacteri
mycot
diseas
nation
center
infecti
diseas
cdc
refer
1
adam
wg
deaver
ka
cochi
sl
et
al
declin
childhood
haemophilu
influenza
type
b
hib
diseas
hib
vaccin
era
jama
19932692216
2
broadhurst
le
erickson
rl
kelley
pw
decreas
invas
haemophilu
influenza
diseas
us
armi
children
1984
1991
jama
199326922731
3
murphi
tv
white
ke
pastor
p
et
al
declin
incid
haemophilu
influenza
type
b
diseas
sinc
introduct
vaccin
jama
hicnet
medic
newslett
page
9
volum
6
number
11
april
25
1993
19932692468
4
fritzel
b
plotkin
efficaci
safeti
haemophilu
influenza
type
b
capsular
polysaccharidetetanu
protein
conjug
vaccin
j
pediatr
199212135562
5
acip
haemophilu
b
conjug
vaccin
prevent
haemophilu
influenza
type
b
diseas
among
infant
children
two
month
age
older
recommend
immun
practic
advisori
committe
acip
mmwr
199140no
rr1
6
acip
diphtheria
tetanu
pertussi
recommend
vaccin
use
prevent
measur
recommend
immun
practic
advisori
committe
acip
mmwr
199140no
rr10
7
acip
pertussi
vaccin
acellular
pertussi
vaccin
reinforc
booster
use
supplementari
acip
statement
recommend
immun
practic
advisori
committe
acip
mmwr
199241no
rr1
8
acip
pertussi
vaccin
acellular
pertussi
vaccin
fourth
recommend
immun
practic
advisori
committe
acip
mmwr
199241no
rr15
use
trade
name
commerci
sourc
identif
impli
endors
public
health
servic
us
depart
health
human
servic
hicnet
medic
newslett
page
10
volum
6
number
11
april
25
1993
dental
news
intern
workshop
explor
oral
manifest
hiv
infect
nidr
research
digest
written
jodi
dove
march
1993
nation
institut
dental
research
second
intern
workshop
oral
manifest
hiv
infect
held
januari
31februari
3
san
francisco
particip
explor
issu
relat
epidemiolog
basic
molecular
virolog
mucos
immunolog
oral
clinic
present
hiv
infect
workshop
organ
dr
john
greenspan
dr
deborah
greenspan
depart
stomatolog
school
dentistri
univers
california
san
francisco
intern
steer
committe
scientif
program
committe
provid
guidanc
confer
drew
260
scientist
39
countri
includ
asia
africa
europ
central
america
south
america
well
unit
state
canada
support
tor
workshop
provid
nation
institut
dental
research
nation
cancer
institut
nation
institut
allergi
infecti
diseas
nih
offic
aid
research
procter
gambl
compani
among
topic
discuss
epidemiolog
hiv
lesion
ethic
profession
respons
public
polici
occup
issu
provis
oral
care
hivposit
popul
salivari
hiv
transmiss
mucos
immun
opportunist
infect
pediatr
hiv
infect
women
issu
recommend
recommend
emerg
workshop
defin
associ
appear
oral
lesion
rate
progress
hiv
establish
univers
terminolog
hivassoci
oral
lesion
look
effect
treatment
oral
manifest
expand
molecular
biolog
studi
understand
relationship
hiv
infect
common
oral
lesion
studi
effect
hiv
therapi
oral
lesion
epidemiolog
sinc
first
intern
workshop
oral
manifest
hiv
infect
conven
five
year
ago
epidemiolog
hiv
infect
hicnet
medic
newslett
page
11
volum
6
number
11
april
25
1993
radic
chang
1988
hiv
infect
detect
report
larg
homosexu
bisexu
male
intraven
drug
user
hemophiliac
today
hiv
infect
seen
heterosexu
male
femal
children
adolesc
predomin
impact
hiv
infect
felt
africa
major
increas
infect
rate
seen
southeast
asia
well
five
hundr
thousand
case
report
date
region
appear
time
research
continu
document
epidemiolog
oral
lesion
hairi
leukoplakia
candidiasi
also
begin
explor
relationship
specif
oral
lesion
hiv
diseas
progress
prognosi
socialpolit
issu
discuss
social
polit
implic
hiv
infect
focus
chang
public
attitud
aid
retribut
indiscrimin
sexual
behavior
drug
use
speaker
also
address
health
care
deliveri
hivinfect
patient
need
educ
public
aid
acquir
saliva
salivari
gland
confer
speaker
describ
transmiss
issu
hivinhibitori
activ
saliva
strength
vari
among
differ
salivari
secret
whole
saliva
greater
inhibitori
effect
submandibular
secret
turn
greater
inhibitori
effect
parotid
secret
research
shown
least
two
mechan
respons
salivari
inhibitori
activ
attribut
hivinhibitori
effect
saliva
1
aggregationagglutin
hiv
saliva
may
promot
clearanc
viru
prevent
reach
target
cell
2
direct
effect
viru
target
cell
topic
discuss
manifest
salivari
gland
diseas
hivinfect
person
current
research
oral
mucos
immun
pediatr
issu
pediatr
aid
recent
emerg
area
intens
interest
earli
accur
diagnosi
proper
treatment
life
expect
hiv
infect
children
tripl
prevent
transmiss
hiv
mother
child
may
possibl
mani
case
particularli
mother
serostatu
known
prior
give
birth
periodont
gingiv
tissu
diseas
hicnet
medic
newslett
page
12
volum
6
number
11
april
25
1993
oral
health
research
continu
explor
periodont
diseas
gingiv
found
individu
hiv
infect
recommend
made
workshop
includ
standard
terminolog
refin
diagnost
marker
standard
studi
design
proper
consider
confound
variabl
result
periodont
therapi
occup
treatment
issu
occup
issu
surround
treatment
hivinfect
individu
treatment
render
hivinfect
health
care
profession
still
command
consider
attent
factor
consider
includ
costbenefit
hiv
test
patienttohealth
care
provid
transmiss
hiv
infect
revers
use
mainstream
versu
dedic
facil
treatment
hivinfect
patient
confer
particip
anticip
third
intern
workshop
oral
manifest
hiv
infect
held
five
year
less
proceed
second
workshop
publish
quintess
compani
late
1993
end
part
1
internet
davidstatcom
fax
1
602
4511165
bitnet
atw1hasuacad
fidonet
111415
amateur
packet
ax25
wb7tpywb7tpyazusana
